Search

Your search keyword '"Boland, P.M."' showing total 12 results
Start Over Author "Boland, P.M." Search Limiters Full Text
12 results on '"Boland, P.M."'

1. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A

Author

Catenacci, D.V.T., Kang, Y.-K., Yoon, H.H., Shim, B.Y., Kim, S.T., Oh, D.-Y., Spira, A.I., Ulahannan, S.V., Avery, E.J., Boland, P.M., Chao, J., Chung, H.C., Gardner, F., Klempner, S.J., Lee, K.-W., Oh, S.C., Peguero, J., Sonbol, M.B., Shen, L., Moehler, M., Sun, J., Li, D., Rosales, M.K., and Park, H.

Published
2022
Full Text
View/download PDF

2. 1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A

Author

Catenacci, D.V., primary, Park, H., additional, Shim, B.Y., additional, Kim, S.T., additional, Oh, D-Y., additional, Spira, A., additional, Ulahannan, S., additional, Avery, E.J., additional, Boland, P.M., additional, Chao, J., additional, Chung, H.C., additional, Gardner, F., additional, Klempner, S.J., additional, Lee, K-W., additional, Oh, S.C., additional, Peguero, J., additional, Sonbol, M.B., additional, Sun, J., additional, Rosales, M.K., additional, and Kang, Y-K., additional

Published
2021
Full Text
View/download PDF

3. 191P First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study

Author

Dean, A., primary, Bekaii-Saab, T., additional, Boland, P.M., additional, Dayyani, F., additional, Mercade, T. Macarulla, additional, Mody, K., additional, Belanger, B., additional, Maxwell, F., additional, Moore, Y., additional, Thiagalingam, A., additional, Wang, T., additional, Zhang, B., additional, and Wainberg, Z.A., additional

Published
2020
Full Text
View/download PDF

4. 193P First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9

Author

Dean, A., primary, Bekaii-Saab, T., additional, Boland, P.M., additional, Dayyani, F., additional, Mercade, T. Macarulla, additional, Mody, K., additional, Belanger, B., additional, Maxwell, F., additional, Moore, Y., additional, Wang, T., additional, Zhang, B., additional, and Wainberg, Z.A., additional

Published
2020
Full Text
View/download PDF

5. 1529P First-line (1L) liposomal irinotecan + 5 fluorouracil/leucovorin (5-FU/LV) + oxaliplatin (OX) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC): Exploratory subgroup analyses of survival by changes in CA 19-9 levels

Author

Dean, A., primary, Bekaii-Saab, T., additional, Boland, P.M., additional, Dayyani, F., additional, Macarulla, T., additional, Mody, K., additional, Belanger, B., additional, Maxwell, F., additional, Moore, Y., additional, Wang, T., additional, Zhang, B., additional, and Wainberg, Z.A., additional

Published
2020
Full Text
View/download PDF

6. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial

Author

Strickler, J.H., primary, Zemla, T., additional, Ou, F.-S., additional, Cercek, A., additional, Wu, C., additional, Sanchez, F.A., additional, Hubbard, J., additional, Jaszewski, B., additional, Bandel, L., additional, Schweitzer, B., additional, Niedzwiecki, D., additional, Kemeny, N., additional, Boland, P.M., additional, Ng, K., additional, and Bekaii-Saab, T., additional

Published
2019
Full Text
View/download PDF

7. BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

Author

Mettu, N.B., primary, Twohy, E., additional, Ou, F.-S., additional, Halfdanarson, T.R., additional, Lenz, H.J., additional, Breakstone, R., additional, Boland, P.M., additional, Crysler, O., additional, Wu, C., additional, Grothey, A., additional, Nixon, A.B., additional, Bolch, E., additional, Niedzwiecki, D., additional, Fruth, B., additional, Schweitzer, B., additional, Elsing, A., additional, Hurwitz, H., additional, Fakih, M.G., additional, and Bekaii-Saab, T., additional

Published
2019
Full Text
View/download PDF

9. 533PD - BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

Author

Mettu, N.B., Twohy, E., Ou, F.-S., Halfdanarson, T.R., Lenz, H.J., Breakstone, R., Boland, P.M., Crysler, O., Wu, C., Grothey, A., Nixon, A.B., Bolch, E., Niedzwiecki, D., Fruth, B., Schweitzer, B., Elsing, A., Hurwitz, H., Fakih, M.G., and Bekaii-Saab, T.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results